Astrazeneca Pharma India Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The agreement aims to accelerate access to SZC, an innovative treatment for hyperkalaemia, across the country.

Hyperkalaemia, a clinically significant condition, disproportionately affects patients with chronic kidney disease (CKD) and heart failure (HF) receiving RAAS inhibitor therapy, which can elevate serum potassium levels. Studies indicate that the condition occurs in up to 50% of CKD patients and 42% of chronic HF patients.

Under the pact, both companies will promote, market, and distribute SZC under different brand names?AstraZeneca as Lokelma and Sun Pharma as Gimliand. AstraZeneca will retain intellectual property rights, marketing authorization, and the import license for the therapy.

This partnership marks a strategic step to expand patient access to SZC in India while leveraging the marketing and distribution networks of both companies.

Praveen Rao Akkinepally, Country president & MD, AstraZeneca Pharma India said, ?At AstraZeneca, we aim to transform care with a focus on increasing early screening, diagnosis, and adoption of guideline-directed medical therapy to improve patient outcomes. This partnership with Sun Pharma for SZC reaffirms AstraZeneca's purpose to deliver innovative, life-changing medicines to patients with Hyperkalaemia across India, coupled with building robust pathways to reach patients in need. With this step, we are poised to significantly expand the reach of this vital therapy and help address the disease burden?.

Kirti Ganorkar, MD, Sun Pharmaceutical Industries, said, ?We are delighted to join hands with AstraZeneca to address the growing challenge of Hyperkalaemia in India. The addition of SZC to our portfolio underscores our unwavering commitment to improving the care of patients with chronic kidney disease. As India?s largest pharmaceutical company and a leader in this therapy area, we remain focused on expanding access to innovative treatments that empower healthcare professionals and enhance the quality of life for patients.?

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company?s standalone net profit shed 2.88% to Rs 54.22 crore in Q2 FY26 as against Rs 55.83 crore posted in Q1 FY26. Revenue from operations rose 6.22% QoQ to Rs 559.09 crore in the quarter ended 30 September 2025. On a year on year (YoY) basis, the company?s net profit surged 41.08% while revenue from operations increased 37.03% in Q2 FY26.

Shares of AstraZeneca Pharma India rose 0.20% to Rs 9,158.50, while Sun Pharmaceutical Industries declined 0.50% to Rs 1,755.10 on the BSE.

Powered by Capital Market - Live News

Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma? whereas Sun Pharma will promote and distribute the therapy as Gimliand?. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.

Powered by Capital Market - Live News

AstraZeneca Pharma India announced the resignation of Manasa. R as company secretary with effect from 28 November 2025.

Powered by Capital Market - Live News

Revenue from operations rose 6.22% QoQ to Rs 559.09 crore in the quarter ended 30 september 2025.

On a year on year (YoY) basis, the company?s net profit surged 41.08% while revenue from operations increased 37.03% in Q2 FY26.

Profit before exceptional items and tax stood at Rs 78.11 crore in Q2 FY26, up 53.06% compared to Rs 51.03 crore in Q2 FY25.

Total expenses rose 33.42% to Rs 487.15 crore in Q2 FY26 over Q2 FY25. During the quarter, purchase of stock-in-trade stood at Rs 432.40 crore (up 71.67% YoY) while employee benefits expense was at Rs 60.45 crore (down 11.15% YoY).

On half-year basis, the company's consolidated net profit climbed 313.10 % to Rs 110.05 crore on 36.43% increase in revenue to Rs 1,085.40 crore in H1 FY26 over H1 FY25.

Bhavana Agrawal, chief financial officer & director of the company, said, ?Our strong Q2/H1 results reflect AstraZeneca?s strong growth trajectory and unwavering commitment to science-led progress. We continue to strengthen our leadership across therapy areas by advancing an innovation-first portfolio that delivers both patient impact and business value. Every approval and milestone underscore our focus on accelerating access to breakthrough treatments and driving sustainable, longterm growth.?

Praveen Akkinepally, country president & managing director, AstraZeneca Pharma India, added, ?Our performance this quarter/in H1, is a clear testament to AstraZeneca?s purpose in action, translating cutting-edge science into life-changing medicines for patients in India. As we scale across our therapy areas, our focus on innovation, partnerships, and patient-centricity is shaping a more accessible and outcomes-driven healthcare ecosystem. Our momentum reinforces our vision to transform healthcare delivery and set new benchmarks for scientific excellence in India.?

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

Powered by Capital Market - Live News